Dr. Raja has over 30 years of experience in studying the basic and clinical aspects of Histocompatibility and Immunogenetics. During the Ph.D. program in the Department of Transplantation Immunology and Immunogenetics, All India Institute of Medical Sciences, Dr. Raja developed DNA-based HLA typing method and studied the diversity of HLA in Asian Indians, and the association between HLA alleles and infectious diseases. During 6 years of postdoctoral training in the Parham laboratory, Stanford University, Dr. Raja defined the KIR genomic diversity in several non-human species. In 2002, Dr.
The Tang lab focuses on translating knowledge on mechanisms of immune tolerance into novel therapeutics for treating autoimmune diabetes and preventing transplant rejection. Currently, two major areas of work are on therapeutic application of regulatory T cell therapy in type 1 diabetes and transplantation and immune modulation to enable immune suppression-free transplant of stem-cell-derived beta cells for treatment of type 1 diabetes.
My research laboratory spans a number of areas within genomics, proteomics, and hematologic malignancies. One major area of research involves the use of targeted, quantitative proteomics to answer important biological questions in myeloma and B-cell leukemia. We are particularly interested in questions related to translational regulation after cancer therapy as well as how clinically-relevant genomic alterations result in phenotypic changes at the level of the proteome. Furthermore, my group includes the UCSF Stephen and Nancy Grand Multiple Myeloma Translational Initiative Laboratory.
